Does liver enzyme monitoring catch real problems with Lipitor?
Lipitor reduces LDL cholesterol by blocking HMG-CoA reductase in the liver. It rarely causes serious liver injury, so routine periodic liver enzyme checks are no longer recommended by most guidelines. Doctors may still order tests at baseline and when symptoms such as unusual fatigue, loss of appetite, or yellowing of the skin appear.
How does the FDA label describe liver risks?
The FDA requires a warning in the prescribing information about rare cases of liver injury. The company must report any severe cases through its adverse-event system. Routine monitoring language was removed years ago after studies showed that routine checks did not improve patient outcomes.
What happens if enzymes rise during Lipitor treatment?
If transaminase levels climb threefold above the upper limit of normal and persist, doctors usually stop the drug. Once levels return to normal, patients can sometimes restart at a lower dose or switch to another statin. Persistent elevation requires further evaluation to rule out other causes.
Why are companies challenging this patent?
Patent disputes over Lipitor’s active ingredient and formulations have occurred in multiple jurisdictions. Companies seek early generic entry by claiming invalidity or non-pinnability. The main composition-of-matter patent expired in 2011, but secondary patents on salt forms and crystal forms have faced challenges.
When does Lipitor’s exclusivity expire?
The primary U.S. patent on atorvastatin calcium expired in 2011. Secondary patents on crystal forms and manufacturing methods have already run their terms or been invalidated. Generic atorvastatin is widely available now at low cost.
Who makes generic Lipitor?
Multiple manufacturers supply generic atorvastatin. Among the largest suppliers include Ranbaxy (now Sun Pharma), Teva, and Mylan (now Viatris). Supply shortages have occurred occasionally due to manufacturing issues.
Can biosimilars enter before patent expiry?
Lipitor is a small-molecule drug, not a biologic, so biosimilar rules do not apply. Generics enter after patents and exclusivities expire through the ANDA process.